CD36 and metabolic syndrome: Podrez et al. have shown that dyslipidemia enhances in vivo thrombosis, whereas genetic deletion of CD36 protects mice from hyperlipidemia-associated platelet activation and the accompanying prothrombotic phenotype (8).